



Synthesis and anti-tubercular activity of novel pyrazol-5(*H*)-one derivatives

Jignesh Priyakant Raval^{a,*}, Arpita Bharatbhai Shah^a, Nilesh Hasmukhbhai Patel^a, Hemul Venubhai Patel^a, Pradip Shantilal Patel^a, Kashyap Kanaiyalal Bhatt^b and Kishor Ratilal Desai^c

^a Department of Pharmaceutical Chemistry, Ashok and Rita Patel Institute of Integrated Study and Research in Biotechnology and Allied Sciences, New Vallabh Vidyanagar, Anand, Gujarat, 388121, India

^b Department of Pharmaceutical Chemistry, Indukaka Ipcowala College of Pharmacy, New Vallabh Vidyanagar, Anand, Gujarat, 38121, India

^c C. G. Bhakta Institute of Biotechnology, Gopal Vidyanagar, Tarsadi, Surat, Gujarat, 394350, India

*Corresponding author at: Department of Pharmaceutical Chemistry, Ashok and Rita Patel Institute of Integrated Study and Research in Biotechnology and Allied Sciences, New Vallabh Vidyanagar, Anand, Gujarat, 388121, India. Tel.: +91.2692.229189; fax: +91.2692.229189.

E-mail address: drijpraval@yahoo.co.in (J. P. Raval).

ARTICLE INFORMATION

Received: 14 July 2010

Received in revised form: 15 October 2010

Accepted: 14 November 2010

Online: 30 June 2011

KEYWORDS

Isonicotinohydrazide

Pyrazol-5(*H*)-ones

Anti-tubercular activity

Anti-mycobacterial activity

Mycobacterium tuberculosis

M. tuberculosis H37Rv

ABSTRACT

In the present investigation, a series of 1-isonicotinoyl-3-methyl-4-(2-(substituted-phenyl)hydrazono)-1*H*-pyrazol-5(*H*)-ones were synthesized by the reaction between isonicotinohydrazide with substituted ethylacetoacetate derivatives using acetic acid as solvent which yielded substituted pyrazol-5(*H*)-one derivatives. Newly synthesized compounds were tested for their *in vitro* anti-tubercular activity against *Mycobacterium tuberculosis* H37Rv using the BACTEC 460 radiometric system. Among the synthesized compounds, 4-(2-(2,6-dichlorophenyl)hydrazono)-1-isonicotinoyl-3-methyl-1*H*-pyrazol-5(4*H*)-one and 4-(2-(1-isonicotinoyl-3-methyl-5-oxo-1*H*-pyrazol-4(5*H*)-ylidene)hydrazinyl)benzene-sulfonamide were found to be more active agent against *M. tuberculosis* H37Rv with minimum inhibitory concentration of 0.0034, 0.0032 μ M at actual MIC 1.66 and 1.64 μ g/mL, respectively.

1. Introduction

In 2009 fell the 126th anniversary of Robert Koch's discovery of the bacillus *Mycobacterium tuberculosis* (MTB) [1], the etiological agent of the well-known respiratory disease Tuberculosis (TB). Despite MTB being identified more than a century ago and with many efficient drugs being discovered during that time to eradicate the disease, TB still remains one of the leading causes of worldwide illness and death. Each year, 424,000 people develop multiple drug-resistant (MDR-TB), a form of TB that does not respond to the standard treatment. It emerges when there is mismanagement of drugs and under investment in quality TB control. It can also be spread from one person to another [2]. Moreover the emergence of multiple drug-resistant strains and, more recently, extensively drug-resistant (XDR-TB) strains makes the discovery and the development of new drugs a priority [3-6]. Also, the emergence of AIDS, decline of socioeconomic standards and a reduced emphasis on tuberculosis control programs contribute to the disease's resurgence in industrialized countries [7]. Thus, Resistance of *M. tuberculosis* strains to anti-mycobacterial agents is an increasing problem worldwide [8-10].

Isoniazid (INH), together with rifampicin and pyrazinamide, constitutes the backbone of a good outcome in the treatment of TB. INH has a simple structure, containing a pyridine ring and a hydrazide group, and both molecules are essential for its high activity against *M. tuberculosis* [11-14]. Development of new drugs against TB derived from already known molecules that have been in use for several years and have been proven safe and efficient is an attractive strategy from an economic, pharmaceutical and clinical viewpoint. Since

INH is a very important drug in the therapeutic arsenal for TB treatment, efforts are being made toward the development of new INH derivatives with greater activity, lower toxicity and fewer side effects [11,15-23]. Literature survey reveals that when INH molecule incorporated on a pyrazole nucleus, shows activity against strains of *M. tuberculosis* both susceptible and resistant to INH [24,25]. Interestingly, other compounds with a halogen-substituted phenyl group showed even greater activity [26]. We believe that the INH moiety is not the only structure responsible for the anti-mycobacterial activity because pyrazoles with different substituents exhibited very different activities [27-30]. Therefore, it is possible that attaching chemical groups that aid the penetration of INH would make *M. tuberculosis* strains more susceptible to this drug [27,29].


The current work describes the synthesis of the novel pyrazol-5(*H*)-one moiety (Scheme 1) with encouraging anti-mycobacterial activity against *M. tuberculosis* H37Rv.

2. Experimental

2.1. Instrumentation

The entire chemicals were supplied by E. Merck (Germany) and SD Fine Chemicals (India). Melting points were determined by open tube capillary method and are uncorrected. Purity of the compounds was checked on thin layer chromatography (TLC) plates (silica gel G) in the solvent system benzene:ethylacetate (5:1) the spots were located under iodine vapors or UV light. IR spectra were obtained on a Perkin-Elmer 1720 FT-IR spectrometer (KBr pellets). ¹H and ¹³C NMR spectra were recorded on a Bruker AC 400 MHz & 100 MHz

spectrometer using TMS as internal standard in DMSO- d_6 /CDCl $_3$, respectively. Mass spectra were recorded on a Bruker Esquire LC-MS using ESI and elemental analyses were performed on a Carlo Erba 1106 elemental analyzer.



Scheme 1

2.2. Synthesis

2.2.1. Ethyl 3-(substituted phenylazo)-2-oxobutanolate (3a)

2-oxobutanolate derivatives were obtained by reacting ethyl acetoacetate (0.01 mol) with appropriate diazonium salt of aromatic amines (0.01 mol) according to the reported method [31].

2.2.2. General procedure (5a-r)

The solution of appropriate 2-oxobutanolate derivative (0.01 mol) and isonicotinohydrazide (0.01 mol) in ethanol (15 mL) and glacial acetic acid (3 mL) were refluxed in a round bottom flask for 7 h. Reaction was monitored by TLC, and after completion the reaction mixture was poured onto crushed ice; the solid mass thus separated, was filtered, washed with water, dried and recrystallized from ethanol to give the desired pyrazolones (5a-r).

1-isonicotinoyl-3-methyl-4-(2-phenylhydrazono)-1H-pyrazol-5(4H)-one (5a): FT-IR (ν , cm^{-1}): 3208-3182 (NH), 1670 (C=O), 1589 (C=N), 3270 (C-H), 2928 (CH $_3$). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.15 (3H, s, CH $_3$), 7.45-8.81 (9H, m, aromatic), 11.56 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 12.91 (CH $_3$), 128.71, 148.11, 162.11 (Ar-C of pyrazol-(5H)-one), 117.90-143.07 (Ar-C). MS (EI, m/z): 307 (M $^+$). Anal. Calcd. for C $_{16}$ H $_{13}$ N $_5$ O $_2$ (307.11): C, 62.53; H, 4.26; N, 22.79. Found: C, 62.18; H, 4.08; N, 22.81%.

1-isonicotinoyl-3-methyl-4-(2-*o*-tolylhydrazono)-1H-pyrazol-5(4H)-one (5b): FT-IR (ν , cm^{-1}): 3208-3180 (NH), 1690 (C=O), 1580 (C=N), 3270 (C-H), 2928 (CH $_3$). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.15 (3H, s, CH $_3$), 2.50 (3H, s, CH $_3$), 7.25-8.80 (8H, m, aromatic), 11.50 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 12.11 (CH $_3$), 21.77 (Ar-CH $_3$), 127.14, 147.22, 163.72 (Ar-C of pyrazol-(5H)-one), 122.50-151.11 (Ar-C). MS (EI, m/z): 322 (M $^+$). Anal. Calcd. for C $_{17}$ H $_{15}$ N $_5$ O $_2$ (321.33): C, 63.54; H, 4.71; N, 21.79. Found: C, 63.11; H, 4.63; N, 21.83%.

1-isonicotinoyl-3-methyl-4-(2-*m*-tolylhydrazono)-1H-pyrazol-5(4H)-one (5c): FT-IR (ν , cm^{-1}): 3208-3180 (NH), 1690 (C=O), 1580 (C=N), 3270 (C-H), 2928 (CH $_3$). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.15 (3H, s, CH $_3$), 2.53 (3H, s, CH $_3$), 7.22-8.80 (8H, m, aromatic), 11.50 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 12.13 (CH $_3$), 21.99 (Ar-CH $_3$), 127.59, 148.10, 163.91 (Ar-C of pyrazol-(5H)-one), 112.90-151.11 (Ar-C). MS (EI, m/z): 321 (M $^+$). Anal. Calcd. for C $_{17}$ H $_{15}$ N $_5$ O $_2$ (321.33): C, 63.54; H, 4.71; N, 21.79. Found: C, 63.41; H, 4.73; N, 21.73%.

1-isonicotinoyl-3-methyl-4-(2-*p*-tolylhydrazono)-1H-pyrazol-5(4H)-one (5d): FT-IR (ν , cm^{-1}): 3208-3180 (NH), 1690 (C=O), 1580 (C=N), 3270 (C-H), 2928 (CH $_3$). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.15 (3H, s, CH $_3$), 2.54 (3H, s, CH $_3$), 7.20-8.80 (8H, m, aromatic), 11.50 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 12.11 (CH $_3$), 21.99 (Ar-CH $_3$), 127.75, 148.26, 163.17 (Ar-C of pyrazol-(5H)-one), 116.90-150.10 (Ar-C). MS (EI, m/z): 321 (M $^+$). Anal. Calcd. for C $_{17}$ H $_{15}$ N $_5$ O $_2$ (321.33): C, 63.54; H, 4.71; N, 21.79. Found: C, 63.44; H, 4.77; N, 21.91%.

1-isonicotinoyl-3-methyl-4-(2-(2-nitrophenyl)hydrazono)-1H-pyrazol-5(4H)-one (5e): FT-IR (ν , cm^{-1}): 3200-3190 (NH), 1680 (C=O), 1582 (C=N), 3270 (C-H), 2928 (CH $_3$), 1344 and 1560 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.15 (3H, s, CH $_3$), 7.40-8.89 (8H, m, aromatic), 11.61 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 11.13 (CH $_3$), 128.72, 148.23, 162.14 (Ar-C of pyrazol-(5H)-one), 127.10-149.70 (Ar-C). MS (EI, m/z): 352 (M $^+$). Anal. Calcd. for C $_{16}$ H $_{12}$ N $_6$ O $_4$ (352.30): C, 54.55; H, 3.43; N, 23.85. Found: C, 54.11; H, 3.63; N, 23.73%.

1-isonicotinoyl-3-methyl-4-(2-(3-nitrophenyl)hydrazono)-1H-pyrazol-5(4H)-one (5f): FT-IR (ν , cm^{-1}): 3200-3190 (NH), 1680 (C=O), 1582 (C=N), 3270 (C-H), 2928 (CH $_3$), 1344 and 1560 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.10 (3H, s, CH $_3$), 7.40-8.89 (8H, m, aromatic), 11.63 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 11.18 (CH $_3$), 129.81, 149.32, 163.21 (Ar-C of pyrazol-(5H)-one), 107.11-148.92 (Ar-C). MS (EI, m/z): 352 (M $^+$). Anal. Calcd. for C $_{16}$ H $_{12}$ N $_6$ O $_4$ (352.30): C, 54.55; H, 3.43; N, 23.85. Found: C, 54.22; H, 3.34; N, 23.77%.

1-isonicotinoyl-3-methyl-4-(2-(4-nitrophenyl)hydrazono)-1H-pyrazol-5(4H)-one (5g): FT-IR (ν , cm^{-1}): 3200-3190 (NH), 1680 (C=O), 1582 (C=N), 3270 (C-H), 2928 (CH $_3$), 1344 and 1560 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.10 (3H, s, CH $_3$), 7.20-8.80 (8H, m, aromatic), 11.62 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 11.20 (CH $_3$), 129.71, 149.12, 163.03 (Ar-C of pyrazol-(5H)-one), 117.21-147.89 (Ar-C). MS (EI, m/z): 352 (M $^+$). Anal. Calcd. for C $_{16}$ H $_{12}$ N $_6$ O $_4$ (352.30): C, 54.55; H, 3.43; N, 23.85. Found: C, 54.42; H, 3.33; N, 23.63%.

4-(2-(2-chlorophenyl)hydrazono)-1-isonicotinoyl-3-methyl-1H-pyrazol-5(4H)-one (5h): FT-IR (ν , cm^{-1}): 3203-3187 (NH), 1680 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH $_3$), 782 (C-Cl). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.13 (3H, s, CH $_3$), 6.50-8.71 (8H, m, aromatic), 11.20 (1H, s, NH). ^{13}C NMR (400 MHz, DMSO- d_6 , δ ppm): 11.39 (CH $_3$), 128.71, 148.12, 162.01 (Ar-C of pyrazol-(5H)-one), 127.21-147.78 (Ar-C). MS (EI, m/z): 342 (M $^+$). Anal. Calcd. for C $_{16}$ H $_{12}$ N $_5$ O $_2$ Cl (341.75): C, 56.23; H, 3.54; N, 20.49. Found: C, 56.31; H, 3.67; N, 20.77%.

4-(2-(3-chlorophenyl)hydrazono)-1-isonicotinoyl-3-methyl-1H-pyrazol-5(4H)-one (5i): FT-IR (ν , cm^{-1}): 3203-3187 (NH), 1680 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH $_3$), 782 (C-Cl). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.13 (3H, s, CH $_3$), 6.80-8.77 (8H, m, aromatic), 11.22 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 11.92 (CH $_3$), 128.18, 148.21, 162.10 (Ar-C of pyrazol-(5H)-one), 117.12-147.87 (Ar-C). MS (EI, m/z): 342 (M $^+$). Anal. Calcd. for C $_{16}$ H $_{12}$ N $_5$ O $_2$ Cl (341.75): C, 56.23; H, 3.54; N, 20.49. Found: C, 56.34; H, 3.69; N, 20.47%.

4-(2-(4-chlorophenyl)hydrazono)-1-isonicotinoyl-3-methyl-1H-pyrazol-5(4H)-one (5j): FT-IR (ν , cm^{-1}): 3203-3187 (NH), 1680 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH $_3$), 782 (C-Cl). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.13 (3H, s, CH $_3$), 7.10-8.79 (8H, m, aromatic), 11.25 (1H, s, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 11.97 (CH $_3$), 128.17, 148.11, 162.11 (Ar-C of pyrazol-

(5*H*-one), 117.72-148.17 (Ar-C). MS (EI, m/z): 342 (M⁺). Anal. Calcd. for C₁₆H₁₂N₅O₂Cl (341.75): C, 56.23; H, 3.54; N, 20.49. Found: C, 56.21; H, 3.69; N, 20.77%.

4-(2-(2,4-dichlorophenyl)hydrazono)-1-isonicotinoyl-3-methyl-1*H*-pyrazol-5(4*H*)-one (**5k**): FT-IR (ν, cm⁻¹): 3203-3187 (NH), 1680 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 782 (C-Cl). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.30 (3H, s, CH₃), 7.55-7.90 (7H, m, aromatic), 11.09 (1H, s, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.18 (CH₃), 127.87, 148.71, 162.91 (Ar-C of pyrazol-(5*H*)-one), 116.92-148.97 (Ar-C). MS (EI, m/z): 377 (M⁺). Anal. Calcd. for C₁₆H₁₁N₅O₂Cl₂ (376.20): C, 51.08; H, 2.95; N, 18.62. Found: C, 51.22; H, 2.89; N, 18.69%.

4-(2-(2,5-dichlorophenyl)hydrazono)-1-isonicotinoyl-3-methyl-1*H*-pyrazol-5(4*H*)-one (**5l**): FT-IR (ν, cm⁻¹): 3203-3187 (NH), 1680 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 782 (C-Cl). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.33 (3H, s, CH₃), 6.77-7.90 (7H, m, aromatic), 11.09 (1H, s, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.11 (CH₃), 127.76, 147.80, 163.80 (Ar-C of pyrazol-(5*H*)-one), 123.72-148.77 (Ar-C). MS (EI, m/z): 377 (M⁺). Anal. Calcd. for C₁₆H₁₁N₅O₂Cl₂ (376.20): C, 51.08; H, 2.95; N, 18.62. Found: C, 51.09; H, 2.99; N, 18.79%.

4-(2-(2,6-dichlorophenyl)hydrazono)-1-isonicotinoyl-3-methyl-1*H*-pyrazol-5(4*H*)-one (**5m**): FT-IR (ν, cm⁻¹): 3203-3187 (NH), 1680 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 782 (C-Cl). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.31 (3H, s, CH₃), 7.02-7.90 (7H, m, aromatic), 13.18 (1H, s, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.18 (CH₃), 127.77, 147.81, 163.83 (Ar-C of pyrazol-(5*H*)-one), 118.77-149.92 (Ar-C). MS (EI, m/z): 377 (M⁺). Anal. Calcd. for C₁₆H₁₁N₅O₂Cl₂ (376.20): C, 51.08; H, 2.95; N, 18.62. Found: C, 51.18; H, 2.91; N, 18.79%.

1-isonicotinoyl-4-(2-(2-methoxyphenyl)hydrazono)-3-methyl-1*H*-pyrazol-5(4*H*)-one (**5n**): FT-IR (ν, cm⁻¹): 3206-3190 (NH), 1689 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 2830 (OCH₃). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.15 (3H, s, CH₃), 3.92 (3H, s, OCH₃), 6.85-8.10 (8H, m, aromatic), 11.18 (1H, s, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.18 (CH₃), 58.69 (OCH₃), 129.96, 147.02, 163.00 (Ar-C of pyrazol-(5*H*)-one), 128.97-148.96 (Ar-C). MS (EI, m/z): 338 (M⁺). Anal. Calcd. for C₁₇H₁₅N₅O₃ (337.12): C, 60.53; H, 4.48; N, 20.76. Found: C, 60.62; H, 4.39; N, 20.72%.

1-isonicotinoyl-4-(2-(3-methoxyphenyl)hydrazono)-3-methyl-1*H*-pyrazol-5(4*H*)-one (**5o**): FT-IR (ν, cm⁻¹): 3206-3190 (NH), 1689 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 2830 (OCH₃). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.17 (3H, s, CH₃), 3.89 (3H, s, OCH₃), 6.27-7.89 (8H, m, aromatic), 12.11 (1H, s, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.18 (CH₃), 59.97 (OCH₃), 129.96, 147.11, 163.19 (Ar-C of pyrazol-(5*H*)-one), 129.91-149.89 (Ar-C). MS (EI, m/z): 338 (M⁺). Anal. Calcd. for C₁₇H₁₅N₅O₃ (337.12): C, 60.53; H, 4.48; N, 20.76. Found: C, 60.74; H, 4.50; N, 20.74%.

1-isonicotinoyl-4-(2-(4-methoxyphenyl)hydrazono)-3-methyl-1*H*-pyrazol-5(4*H*)-one (**5p**): FT-IR (ν, cm⁻¹): 3206-3190 (NH), 1689 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 2830 (OCH₃). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.11 (3H, s, CH₃), 3.89 (3H, s, OCH₃), 7.02-7.89 (8H, m, aromatic), 12.15 (1H, s, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.18 (CH₃), 59.22 (OCH₃), 129.98, 147.02, 163.00 (Ar-C of pyrazol-(5*H*)-one), 128.19-147.97 (Ar-C). MS (EI, m/z): 338 (M⁺). Anal. Calcd. for C₁₇H₁₅N₅O₃ (337.12): C, 60.53; H, 4.48; N, 20.76. Found: C, 60.65; H, 4.48; N, 20.78%.

4-(2-(2,4-dimethoxyphenyl)hydrazono)-1-isonicotinoyl-3-methyl-1*H*-pyrazol-5(4*H*)-one (**5q**): FT-IR (ν, cm⁻¹): 3210-3190 (NH), 1690 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 2830 (OCH₃). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.10 (3H, s, CH₃), 3.50 (3H, s, CH₃), 3.89 (3H, s, OCH₃), 6.77-8.81 (7H, m, aromatic), 11.11 (1H, s, NH). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.20 (CH₃), 57.71 (2xOCH₃), 129.89, 147.11, 164.11 (Ar-C of pyrazol-(5*H*)-one), 121.19-149.77 (Ar-C). MS (EI, m/z): 368 (M⁺). Anal. Calcd. for C₁₈H₁₇N₅O₄ (367.36): C, 58.85; H, 4.66; N, 19.06. Found: C, 58.95; H, 4.78; N, 19.18%.

4-(2-(1-isonicotinoyl-3-methyl-5-oxo-1*H*-pyrazol-4(5*H*)-ylidene)hydrazinyl)benzene-sulfonamide (**5r**): FT-IR (ν, cm⁻¹): 3206-3190 (NH), 1689 (C=O), 1586 (C=N), 3270 (C-H), 2928 (CH₃), 1339-1337, 1147-1137 (SO₂), 3440 (NH₂). ¹H NMR (400 MHz, DMSO-*d*₆, δ ppm): 2.15 (3H, s, CH₃), 6.91-7.89 (8H, m, aromatic), 13.11 (1H, s, NH), 8.83 (2H, s, SO₂NH₂). ¹³C NMR (100 MHz, DMSO-*d*₆, δ ppm): 12.29 (CH₃), 127.77, 147.21, 165.09 (Ar-C of pyrazol-(5*H*)-one), 129.30-148.19 (Ar-C). MS (EI, m/z): 387 (M⁺). Anal. Calcd. for C₁₆H₁₄N₆O₄S (386.39): C, 49.74; H, 3.65; N, 21.75. Found: C, 49.98; H, 3.79; N, 21.79%.

2.3. Biology

The primary screening was conducted at a concentration of 6.25 μg/mL (or molar equivalent of highest molecular weight compound in a series of congeners) against *M. tuberculosis* H37Rv (ATCC27294) in BACTEC 12B medium using the BACTEC 460 radiometric system [32,33]. Compounds demonstrating at least 90% inhibition in the primary screen were re-examined at lower concentration (MIC) in broth microdilution assay with Alamar Blue. The MIC was defined as the lowest concentration inhibiting 99% of the inoculum. Concurrent with the determination of MICs, compounds were tested for cytotoxicity (IC₅₀) in VERO at concentration equal to and greater than the MIC for *M. tuberculosis* H37Rv after 72 h of exposure, viability is assessed on the basis of cellular conversion of MTT into a formazan product using the Promega Cell Titer 96 Non-radioactive Cell proliferation assay.

3. Results and discussion

3.1. Chemistry

1-isonicotinoyl-3-methyl-4-(2-(substituted phenyl)hydrazono)-1*H*-pyrazol-5(4*H*)-ones (**5a-r**) described in this study are shown in (Table 1) and a reaction sequence for the preparation is outlined in (Scheme 1). The ethyl 3-(substituted phenyl)azo-2-oxobutanolate (**3a-r**) were prepared by reacting ethylacetoacetate with appropriate diazonium salt of aromatic amines in the presence of ethanol. Reaction between this newly synthesized 2-oxobutanolate derivatives and isonicotino hydrazide in acetic acid (reaction mediator) and ethanol as solvent led to the synthesis of novel pyrazolones (**5a-r**) in 60-92% yield after recrystallization with ethanol. The purity of the compounds was checked by TLC and elemental analyses. Both analytical and spectral data (¹H and ¹³C NMR, IR and MS) of all the synthesized compounds were in full agreement with the proposed structures. Final compounds in general, in the infrared spectra (IR), revealed NH, C=O, C=N, C-N, and CH₃ peaks at 3220, 1680, 1590, 1320, 2928 cm⁻¹, respectively.

In the nuclear magnetic resonance spectra (¹H and ¹³C NMR) the signals of the respective protons of the prepared compounds were verified on the basis of their chemical shifts, multiplicities and coupling constants. The spectra showed ¹H NMR singlet at δ range 2.10-2.33 ppm corresponding to methyl group; multiplet at, δ range 6.50-8.80 ppm for aromatic protons; singlet at δ range 11.09-13.18 ppm for NH proton. Similarly, ¹³C NMR signals at δ range 11.18-12.91 ppm (C14 of CH₃), 127.14-129.96 ppm (C13), 147.02-149.32 ppm (C12) and 162.11-165.09 ppm (C11) of pyrazolone ring and signals at δ range 107.11-151.11 ppm of aromatic carbons, respectively. The elemental analysis results were within ±0.4% of the theoretical values.

3.2. In-vitro Anti-mycobacterial activity

Among the ring substituted pyrazolone derivatives (**5a-r**) were tested for their anti-mycobacterial activity in vitro against *M. tuberculosis* H37Rv using the BACTEC 460 radiometric system.

Table 1. Characterization data of the synthesized compounds, **5a-r**.

Compound	R	Yield (%)	Melting Point (°C)	Mol. Formula	Mol. wt. (g)	UV, λ_{max} (CH ₃ OH) (nm)
5a	H	80	198-200	C ₁₆ H ₁₃ N ₅ O ₂	307.31	238.4
5b	2-CH ₃	70	240-241	C ₁₇ H ₁₅ N ₅ O ₂	321.33	369.3
5c	3-CH ₃	60	170-173	C ₁₇ H ₁₅ N ₅ O ₂	321.33	373.7
5d	4-CH ₃	65	105-107	C ₁₇ H ₁₅ N ₅ O ₂	321.33	379.9
5e	2-NO ₂	75	185-186	C ₁₆ H ₁₂ N ₆ O ₄	352.30	367.6
5f	3-NO ₂	68	250-252	C ₁₆ H ₁₂ N ₆ O ₄	352.30	384.8
5g	4-NO ₂	78	210-212	C ₁₆ H ₁₂ N ₆ O ₄	352.30	389.9
5h	2-Cl	72	130-132	C ₁₆ H ₁₂ ClN ₅ O ₂	341.75	363.2
5i	3-Cl	79	125-126	C ₁₆ H ₁₂ ClN ₅ O ₂	341.75	377.6
5j	4-Cl	75	190-192	C ₁₆ H ₁₂ ClN ₅ O ₂	341.75	378.8
5k	2,4-Cl ₂	77	187-189	C ₁₆ H ₁₁ Cl ₂ N ₅ O ₂	376.20	376.7
5l	2,5-Cl ₂	79	189-191	C ₁₆ H ₁₁ Cl ₂ N ₅ O ₂	376.20	375.2
5m	2,6-Cl ₂	82	192-194	C ₁₆ H ₁₁ Cl ₂ N ₅ O ₂	376.20	376.9
5n	2-OCH ₃	72	144-147	C ₁₇ H ₁₅ N ₅ O ₃	337.33	355.9
5o	3-OCH ₃	58	149-150	C ₁₇ H ₁₅ N ₅ O ₃	337.33	359.7
5p	4-OCH ₃	69	152-154	C ₁₇ H ₁₅ N ₅ O ₃	337.33	357.8
5q	2,4-OCH ₃	72	167-169	C ₁₈ H ₁₇ N ₅ O ₄	367.36	483.4
5r	4-SO ₂ NH ₂	77	177-179	C ₁₆ H ₁₄ N ₆ O ₄ S	386.89	478.4

Table 2. Anti-mycobacterial activity of the synthesized compounds against *M. tuberculosis* H37Rv.

Compound	Primary Screen (6.25 μ g/mL)	% Inhibition	Concentration, μ M	Actual MIC, μ g/mL
5a	>6.25	64	0.0354	-
5b	>6.25	12	0.1140	6.25
5c	>6.25	32	0.1706	-
5d	>6.25	28	0.1135	6.25
5e	>6.25	44	0.0167	-
5f	>6.25	14	0.0132	6.25
5g	>6.25	26	0.0142	6.25
5h	>6.25	63	0.0130	6.25
5i	6.25	62	0.0138	6.25
5j	>6.25	64	0.0133	6.25
5k	>6.25	69	0.0118	5.67
5l	6.25	96	0.0084	5.77
5m	6.25	98	0.0034	1.66
5n	>6.25	94	0.0092	4.12
5o	>6.25	88	0.0108	6.25
5p	>6.25	86	0.0103	6.25
5q	>6.25	89	0.0107	6.25
5r	6.25	98	0.0032	1.64

Isoniazid (0.025 - 0.05 μ g/mL).

The results are summarized in Table 2 with INH, a standard used for comparison. Among the 18 newly synthesized compounds, **5l**, **5m**, **5n** and **5r** produced highest efficacy and exhibited >90% inhibition at a concentration of 0.0084, 0.0034, 0.0092 and 0.0032 μ M followed by **5o**, **5p** and **5q** which showed moderate to good inhibitory activity with 0.0108 μ M, 0.0103 μ M and 0.0107 μ M, respectively. Thus, the 2,6-dichloro and 4-SO₂NH₂ groups substitution derivatives displayed relatively higher inhibitory activity in general. However, the electron rich groups such as, 2,5-chloro, 2-methoxy, 3-methoxy, 4-methoxy, and 2,4-dimethoxy substituted analogue compounds produced significant increase in inhibitory activity against *M. tuberculosis* H37Rv. On the other hand, pyrazolone analogues with methyl group substitution **5b**, **5c**, **5d** and hydrogen substitution **5a** showed relatively low inhibitory activity against *M. tuberculosis* H37Rv. Instead (CH₃) group and (NO₂) group substitution at phenyl ring in pyrazolone analogue worsens the anti-mycobacterial activity.

All the newly synthesized compounds (**5a-r**) were tested for cytotoxicity (IC₅₀) in VERO cells at concentrations of 62.5 μ g/mL. After 72 h of exposure, viability was assessed on the basis of cellular conversion of MTT into a formazan product using the Promega Cell Titer 96 Non-radioactive Cell proliferation method. All the active compounds were found to be non-toxic till 62.5 μ g/mL.

4. Conclusion

Among the newer derivatives, it is conceivable that derivatives showing anti-mycobacterial activity can be further modified to exhibit better potency than the standard drugs. The pyrazolone derivatives discovered in this study may provide valuable therapeutic intervention for the treatment of anti-tubercular diseases.

Acknowledgement

The author (J. P. Raval) wishes to express his thanks to Tuberculosis Antimicrobial Acquisition and Coordinating Facility (NIAID, NIH, USA) for in vitro anti-mycobacterial screening. We thank Mr. Priyakant R. Raval (Cyanamid India Limited, Atul) for providing analytical and spectral data.

References

- [1]. Brock, T. D. Robert Koch. A Life in Medicine and Bacteriology, Science Tech. Madison, WI, 1998.
- [2]. World Health Organization, 2009, http://www.who.int/tb/publications/global_report/2009/update/en/index.html.
- [3]. Janin, Y. L. *Bioorg. Med. Chem.* **2007**, *15*, 2479-2513.
- [4]. Gutierrez-Lugo, M. T.; Bewley, C. J. *Med. Chem.* **2008**, *51*, 2606-2612.
- [5]. http://www.who.int/tb/challenges/xdr/xdr_mdr_factsheet_2007_en.pdf.
- [6]. Manetti, F.; Magnani, M.; Castagnolo, D.; Passalacqua, L.; Botta, M.; Corelli, F.; Saggi, M.; Deidda, D.; De Logu, A. *Chem. Med. Chem.* **2006**, *1*, 973-989.
- [7]. Barnes, P. F.; Blotch, A. B.; Davidson, P. T.; Snider Jr. D. E.; *N. Engl. J. Med.* **1991**, *324*, 1644-1649.
- [8]. Sbarbaro, J. A. *Chest.* **1997**, *111*, 1149-1150.
- [9]. Fujiwara, P. I.; Cook, S. V.; Rutherford, C. M.; Crawford, J. T.; Glickman, S. E.; Kreiswirth, B. N.; Sachdev, Osahan, S. S.; Ebrahimzadeh, A.; Frieden, T. R. *Arch. Intern. Med.* **1997**, *157*, 531-535.
- [10]. Bibikova, M. V.; Borisova, N. A.; Orekhov, S. N.; Katlinskii, A. V. *Antibiot Khimioter.* **2006**, *51(1)*, 22-27.
- [11]. Bernstein, J.; Lott, W. A.; Steinberg, B. A.; Yale, H. L. *Am. Rev. Tuberc.* **1952**, *65*, 357-364.
- [12]. Wang, J. Y.; Burger, R. M.; Drlica, K. *Antimicrob. Agents Chemother.* **1998**, *42*, 709-711.
- [13]. Slayden, R. A.; Lee, R. E.; Barry, III. C. E. *Mol. Microbiol.* **2000**, *38*, 514-525.
- [14]. Timmns, G. S.; Deretic, V. *Mol. Microbiol.* **2006**, *62*, 1220-1227.
- [15]. Almeida, de Silva P.; Ainsa, J. A. Drugs and drug interactions. In: Palomino, J. C.; Leao, S. C.; Ritacco, V. Editors. Tuberculosis 2007. From basic science to patient care. <http://www.TuberculosisTextbook.com>.
- [16]. Burman, W. J.; Gallicano, K.; Peloquin, C. *Clin. Pharmacokin.* **2001**, *40*, 327-341.
- [17]. Chen, P.; Gearhart, J.; Protopopova, M.; Einck, L.; Nacy, C. A. *J. Antimicrob. Chemother.* **2006**, *58*, 332-337.
- [18]. Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. *J. Antimicrob. Agents Chemother.* **2005**, *49*, 1447-1454.

- [19]. Jia, L.; Tomaszewski, J. E.; Hanrahan, C. *Brit. J. Pharmacol.* **2005**, *144*, 80-87.
- [20]. Protopopova, M.; Hanrahan, C.; Nikonenko, B. *J. Antimicrob. Chemoth.* **2005**, *56*, 968-974.
- [21]. Cocco, M. T.; Congiu, C.; Onnis, V.; Pusceddu, M. C.; Shivo, M. L.; Logu, A. *Eur. J. Med. Chem.* **1999**, *34*, 1071-1076.
- [22]. Costi, R.; Artico, M.; Santo, D. R. *Med. Chem. Res.* **1999**, *9*, 408-423.
- [23]. Hudson, A.; Imamura, T.; Gutteridge, W.; Kanyok, T.; Nunn, P. The Current anti-TB drug research and development pipeline. In: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 2003.
- [24]. Castagnolo, D.; De Logu, A.; Radi, M.; Bechi, B.; Manetti, F.; Magnani, M.; Supino, S.; Meleddu, R.; Chisu, L.; Botta, M. *Bioorg. Med. Chem.* **2008**, *16(18)*, 587-8591.
- [25]. Castagnolo, D.; Manetti, F.; Radi, M.; Bechi, B.; Pagano, M.; De Logu, A.; Meleddu, R.; Saddi, M.; Botta, M. *Bioorg. Med. Chem.* **2009**, *17(15)*, 5716-5721.
- [26]. Shaharyar, M.; Siddiqui, A. A.; Ali, M. A.; Sriram, D.; Yogeeswari, P. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 3947-3949.
- [27]. Maccari, R.; Ottana, R.; Vigorita, M. G. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 2509-2513.
- [28]. Zampieri, D.; Mamolo, M. G.; Laurini, E.; Scialino, G.; Banfi, E.; Vio L. *Bioorg. Med. Chem.* **2008**, *16(8)*, 4516- 4522.
- [29]. Almeida de Silva, P. E.; Ramos, D. F.; Bonacorso, H. G.; Agustina, I. De la Iglesia, Oliveira, M. R.; Coelho, T.; Navarini, J.; Morbidoni, H. R.; Zanatta, N.; Martins, M. A. P. *Inter. J. Antimicrob. Agents* **2008**, *32*, 139-144.
- [30]. Velaparthi, S.; Brunsteiner, M.; Uddin, R.; Wan, B.; Franzblau, S. G.; Petukhov, P. A. *J. Med. Chem.* **2008**, *51(7)*, 1999-2002.
- [31]. Shrivastava, M. K.; Padmaja, P.; Jain, R.; Tomar, S. *Indian J. Chem.* **2000**, *77*, 44-47.
- [32]. Interleid, B. Antibiotic in Laboratory Medicine, In: Lorian, V. editors, third edition, Williams and Wilkins, Baltimore, 1991, pp. 134.
- [33]. Colins, L.; Franzblau, S. G. *Antimicrob. Agents Chemother.* **1997**, *41*, 1004-1009.